Companies / Sagimet Biosciences
Sagimet Biosciences
United States
Sagimet Biosciences is a clinical-stage biopharmaceutical company advancing a portfolio of novel fatty acid synthase (FASN) inhibitors.
Sagimet Biosciences, based in United States, has 4 investors on file, among them Altium Capital, Kleiner Perkins and NEA. Its site was last checked 13 Nov 2026: site answers.
Investors
4 investors on file| Investor | Evidence | Type |
|---|---|---|
| Portfolio page | Venture capital | |
| Portfolio page | Venture capital | |
| Portfolio page | Venture capital | |
| Portfolio page | Investor |
In the news
3 headlines naming Sagimet BiosciencesEach headline is matched with evidence and opens on its outlet. Some come through the GDELT Project.
A company is shown only after its own site answers and carries its name. Sites are checked again on a schedule, because domains lapse and get bought. Round stages and dates come from Fundup AI; investor links come from portfolio pages and rounds; other facts name their source when you point at them. How we grade the data
Get Sagimet Biosciences and its investors as data
Look up any company's investors, or any investor's full portfolio, through one API key or MCP. A free account also opens Ask AI searches and alerts when Altium Capital adds a company.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/companies/sagimet.com/investors
# also
GET /v1/companies/sagimet.com
GET /v1/companies/sagimet.com/news